In today's episode, your hosts Jennie and Jordan uncover the fascinating history, deep science, real-world results, and controversies surrounding GLP-1 receptor agonists
2024;59(Suppl 1):S5275
Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh
Releasing Q2 earnings on Monday, Hims & Hers Co-Founder and CEO Andrew Dudem said users of its personalized GLP-1 treatment plans had lost an average 10.3% of their body weight over six months, and that only 25% of them had discontinued treatment, particularly encouraging when considering discontinuation rates in certain publicly available studies reached approximately 80% percent by six months. Saying that personalized treatments allow patients to receive clear treatment instructions and educational content while also accessing tools such as water intake trackers and calorie counters, Dudem complained of pushback from traditional incumbents. During its own earnings call on Wednesday, Novo Nordisk doubled down against GLP-1 compounders that it says are still around despite the end of an FDA-granted grace period in May
GLP-1 medications work by addressing appetite dysregulation at the brain level, which is relevant regardless of your weight loss target
The various administration methods each have advantages depending on whether the eczema is localized or widespread
